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Abstract
Background: Determining whether methicillin-resistant Staphylococcus aureus (MRSA) is a true causative pathogen
or reflective of colonization when MRSA is cultured from the respiratory tract remains important in treating patients
with pneumonia.
Methods: We evaluated the bacterial microbiota in bronchoalveolar lavage fluid (BALF) using the clone library
method with a 16S ribosomal RNA (rRNA) gene analysis in 42 patients from a pneumonia registry who had MRSA
cultured from their sputum or BALF samples. Patients were divided into two groups: those treated with (Group A)
or without (Group B) anti-MRSA agents, and their clinical features were compared.
Results: Among 248 patients with pneumonia, 42 patients who had MRSA cultured from the respiratory tract were
analyzed (Group A: 13 patients, Group B: 29 patients). No clones of S. aureus were detected in the BALF of 20 out of
42 patients. Twenty-eight of 29 patients in Group B showed favorable clinical outcomes, indicating that these patients
had non-MRSA pneumonia. Using a microflora analysis of the BALF, the S. aureus phylotype was predominant in 5 of 28
(17.9 %) patients among the detected bacterial phylotypes, but a minor population (the percentage of clones≤ 10 %) in
19 (67.9 %) of 28 patients. A statistical analysis revealed no positive relationship between the percentage of clones of
the S. aureus phylotype and risk factors of MRSA pneumonia.
Conclusions: The molecular method using BALF specimens suggests that conventional cultivation method results may
mislead true causative pathogens, especially in patients with MRSA pneumonia. Further studies are necessary to
elucidate these clinically important issues.
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Background
Patients with nosocomial pneumonia caused by methicillin-
resistant Staphylococcus aureus (MRSA) have been increas-
ing over the past half century. Approximately 20–40 % of
all hospital-acquired pneumonia (HAP), ventilator-
associated pneumonia (VAP) [1, 2] and the number of
MRSA pneumonia patients is increasing in step with aging
of the population [3]. Several guidelines [4, 5], including
Japanese guidelines for nursing and healthcare-associated
pneumonia (NHCAP) [6] and HAP [7, 8], suggest the use
of anti-MRSA antimicrobials in pneumonia patients when
the risks of MRSA are suggested. However, there have been
only a few clinical studies that describe the pathogenicity of
MRSA in bacterial pneumonia and accurate diagnostic
methods for evaluating MRSA pneumonia [9–11]. Gener-
ally, the diagnostic criteria of respiratory infection caused
by MRSA are positive results of a quantitative culture of
MRSA over 106 colony forming units (CFU)/ml in sputum
samples, 104 CFU/ml in lower respiratory specimens and/
or phagocytosis of S. aureus by polymorphonuclear neutro-
phils [4]. However, it is occasionally difficult to differentiate
whether the detected MRSA is a true causative pathogen of
pneumonia or only reflective of colonization when MRSA
is cultured from the lower respiratory tract samples. Physi-
cians should carefully consider whether or not cultured
MRSA is actually causative in each case because many pa-
tients fulfill these criteria and improve without anti-MRSA
agents in real-world clinical settings. Differentiation of
MRSA as a cause of pneumonia or merely colonization re-
mains an important clinical issue and is of a particular
interest in clinical settings.
We hypothesized that the percentage of S. aureus clones
in bronchoalveolar lavage fluid (BALF) directly obtained
from the affected lesions of pneumonia identified by chest
CT might be helpful to distinguish true MRSA pneumonia
from colonization of MRSA. In the present study, we used
the data from the pneumonia registry, which included 16S
ribosomal RNA gene analyses of BALF, and patients with
pneumonia in whom MRSA was cultured from the respira-
tory samples were enrolled. Then we divided these patients
into two groups: Group A included MRSA pneumonia pa-
tients treated with anti-MRSA agents and Group B were
patients with MRSA cultured from respiratory samples but
who improved without anti-MRSA treatment, and the clin-
ical features of these two groups were compared.
Methods
Patients
Among 248 Japanese patients with community-acquired
pneumonia (CAP), healthcare-associated pneumonia
(HCAP) and HAP at the University of Occupational and
Environmental Health, Japan and referred hospitals be-
tween April 2010 and January 2015, 42 patients with
positive cultures for MRSA from respiratory specimens
(i.e., sputum, endobronchial aspirates and BALF) were en-
rolled (Fig. 1). This cohort included patients in previous
studies of CAP [12] and HCAP [13]. Patients who had
MRSA positively cultured from respiratory specimens were
divided into two groups: Group A consisted of patients that
had been treated with anti-MRSA agents, and Group B in-
cluded patients that had been treated without anti-MRSA
agents, and the clinical features of these two groups were
compared. This study was approved by the Human and
Animal Ethics Review Committee of the University of Oc-
cupational and Environmental Health, Japan (No.09-118),
and all patients provided their written informed consent.
Definitions
The diagnosis of pneumonia was made by the fulfillment of
the following three criteria: (1) at least one of the following
248 patients with pneumonia who 
were examined by bronchoscopy







Fig. 1 A flow chart of the study participants. CAP: community-acquired pneumonia, HCAP: healthcare-associated pneumonia, HAP: hospital-acquired
pneumonia, MRSA: methicillin-resistant Staphylococcus aureus, BALF: bronchoalveolar lavage fluid
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clinical symptoms (a fever ≥ 37 °C, cough, purulent sputum,
moist rales, pleural pain, dyspnea, or tachypnea); (2) new in-
filtrates on a chest X-ray or computed tomography (CT);
and (3) at least one sign of systemic inflammation (a white
blood cell (WBC) count > 10,000/mm3 or < 4,500/mm3 or
an increased C-reactive protein (CRP) level). The definitions
of CAP, HCAP and HAP were made according to the Infec-
tious Diseases Society of America (IDSA)/American Thor-
acic Society (ATS) guidelines. Briefly, CAP was defined as
pneumonia acquired in the community with no risk factors
for HCAP. HCAP was defined as pneumonia acquired in
the community with one or more of the following risk fac-
tors: (a) hospitalization for 2 days in the preceding 90 days;
(b) residence in a nursing home or extended care facility; (c)
home infusion therapy (including antibiotics); (d) long-term
dialysis (including hemodialysis and peritoneal dialysis)
within 30 days of entering the study; and (e) home wound
care. HAP was defined as pneumonia acquired in the hos-
pital ≥ 48 h after admission [4, 14]. The criteria for aspir-
ation risk factors, such as neurologic dysphagia, anatomical
abnormalities of the upper aerodigestive tract and poor oral
hygiene defined by Marik et al. [15] were used, and patients
with gastroesophageal disorders (including disruption of the
gastroesophageal junction) were included in this study.
Data and sample collection
The laboratory findings and radiological information on
chest X-rays and/or CT were collected. BALF specimens
using 40 ml of sterile saline were obtained from lung le-
sions of pneumonia, as previously described [12, 13].
Evaluation of the clinical efficacy
The clinical efficacies of the antimicrobials were evaluated
by an improvement in the clinical symptoms, laboratory
and chest radiography findings, which fulfill the definitions
proposed by the Japan Society of Chemotherapy [16]. The
treatment medication for pneumonia was considered to be
clinically “effective” when more than three of the following
criteria were satisfied: (1) improvement or complete reso-
lution of the clinical symptoms, (2) improvement in the
body temperature to ≤ 37 °C, (3) chest radiography score
of ≤ 70 % of the previous value, (4) WBC count ≤ 9,000/
mm3 and (5) CRP level ≤ 30 % of the previous value. When
the efficacy criteria were not satisfied for any reason, the
case was considered to be “ineffective.” Physicians followed
the guidelines for CAP, HCAP and HAP to use anti-MRSA
agents as the first antimicrobial treatment. As the present
study was a retrospective cohort study, there were no strict
criteria that regulate an intervention of anti-MRSA therapy
as an additive antibiotic treatment, but clinical response to
antibiotics was firstly evaluated three days after the start of
antimicrobial treatment, physicians decided to add anti-
MRSA agents when the clinical response to antimicrobials
were ineffective with positive culture results for MRSA.
Criteria for the identification of bacterial isolates
Microbiological evaluation using cultivation methods
Cultivation of BALF and sputum samples was performed
as previously described [12, 13]. The samples were inocu-
lated onto the appropriate Vitek apparatus with or without
the associated API identification strip using the Vitek 2 ap-
paratus (bioMerieux), and bacterial identification was con-
firmed according to an identification percentage of more
than or equal to 90 %. When the percentage was less than
90 %, subsequent bacterial identification was performed
using API. Each macroscopically recognized bacterial col-
ony containing normal bacterial flora was recorded as nor-
mal flora. All S. aureus isolates were identified according
to a morphologic analysis of the bacterial colony, Gram
staining and catalase and coagulase tests. MRSA was iden-
tified if the minimum inhibitory concentration of oxacillin
was ≥ 4 μg/ml.
Total cell count, cell lysis efficiency analysis and bacterial
identification using the molecular method
Using BALF specimens, the total bacterial cell count and
cell lysis efficiency were evaluated using epifluorescent mi-
croscopy, and DNA extraction, amplification of the 16S
rRNA gene using polymerase chain reaction (PCR), clone
library construction and a sequencing analysis were per-
formed, as previously described [12, 13, 17–20]. De-
tected DNA sequences were then compared with those of
the type strains using the basic local alignment search tool
(BLAST) algorithm, as described previously. The 16S
rRNA gene sequences of type strains were obtained from
the DNA Data Bank of Japan (http://www.ddbj.nig.ac.jp/)
and the Ribosomal Database Project II (http://rdp.cme.m
su.edu/) [12, 13, 17–20].
Evaluation of the radiologic findings
Chest X-rays or CT performed within 48 h of the onset
of pneumonia were analyzed and evaluated by two experi-
enced respirologists without any clinical information.
Radiological findings were sorted into four different pat-
terns as follows: “lobar pneumonia pattern” that showed an
air-space consolidation limited to one lobe or one segment,
“aspiration pneumonia pattern” that showed pulmonary in-
filtrations in the bilateral lower lobes, “pulmonary abscess
pattern” where the infiltrations accompanied the cavity and
“others” that included any other remaining patterns of
pneumonia, such as bronchopneumonia, according to pre-
vious reports [21, 22].
Statistical analysis
The baseline characteristics were summarized using de-
scriptive statistics. Continuous variables were compared
using the Mann–Whitney U-test and Student’s t-tests, while
categorical variables were compared using Fisher’s exact test
or the chi-square test, as appropriate. The SPSS software
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package (version 19) was used for the statistical analysis,
and a P <0.05 was considered statistically significant.
Results
Clinical characteristics and laboratory findings of the
participants
The clinical characteristics and laboratory findings of 42 pa-
tients from whom MRSA was detected are shown in
Table 1. Thirteen (31.0 %) and 29 (69.0 %) patients had
been treated with (Group A) and without (Group B) anti-
MRSA antimicrobials. Between Groups A and B, the rate of
patients with malignancy was significantly higher in Group
B (37.9 %, 11/29) than in Group A (7.7 %, 1/13) (p = 0.016)
(Table 1). In these 42 patients, the risk factors of MRSA,
such as the use of corticosteroid or immunosuppressants
(14.3 %), nasogastric tube feeding or percutaneous gastros-
tomy tube feeding (7.1 %), antibiotics use within 90 days
(28.6 %), detection of MRSA within 90 days (23.1 %), were
observed, however, these findings were not significantly dif-
ferent between the groups (Table 1). In addition, patients
with aspiration risks were observed in 54.8 % of the total
cohort. Group B included significantly more HCAP pa-
tients than Group A (P = 0.015), however, the radiological
findings were not significantly different between Groups A
and B (Table 1).
Comparison between bacterial cultivation and the clone
library method of 16S rRNA gene sequencing analysis
Table 2 shows the comparison of the results of the bac-
terial culture and bacterial floral analysis using the 16S
rRNA gene with the clinical course of the patients. Cul-
tivation results demonstrated that MRSA were isolated
in all 19 patients in whom sputum culture was per-
formed, and 37 of 41 (90.5 %) patients excluding No. 33
(BALF culture was not analyzed) showed positive culture
results of MRSA using BALF samples. The molecular
method detected the S. aureus phylotype in 22 patients,
whereas 20 patients showed no S. aureus phylotypes in the
BALF samples (Table 2). In Group A, S. aureus was de-
tected in 69.2 % (9 of 13, Cases 1–9) of the patients by both
cultivation methods and the molecular method, and the
molecular method demonstrated that the S. aureus phylo-
type was predominant in 38.5 % (5 of 13, Cases 1–5) of the
BALF specimens (Table 2). In 8 of 13 (61.5 %) Group A pa-
tients where S. aureus was not the predominant phylotype
(Cases 6–13), S. aureus comprised a minor population (per-
centage of clones ≤ 10 %). In these 8 patients (Cases 6–13),
no discrepancies were observed between the most occupied
bacterial phylotypes by the molecular method and the clin-
ical outcomes after antibiotic therapy. All of the patients
with poor clinical outcomes in Group A (5 of 13, Cases 1,
4, 6, 10, 11) had obvious complicated poor prognostic fac-
tors, such as asphyxiation due to tracheobronchial secre-
tion, exacerbation of heart failure and aspergillosis.
In Group B, 96.5 % of patients (28 of 29, Cases 14–16,
18–42) showed good clinical outcomes without anti-MRSA
antimicrobials; one patient (Case 17) died because of as-
phyxiation due to tracheobronchial secretion. The S.
aureus phylotype was a minor population (percentage
of clones ≤10 %) or undetectable (0 %) in 10.7 % (3 of
28, Cases 24–26) and 57.1 % (16 of 28, Cases 27–42), re-
spectively, of the patients in Group B who had good clin-
ical outcomes. In addition, 5 of these 28 patients (Cases
14–18) showed that the S. aureus phylotype was the
most detected phylotype, including one patient (Case
14) with 100 % of the percentage of clones of S. aureus
phylotype.
Correlation of the percentage of clones of S. aureus
phylotype and risk factors of MRSA pneumonia
Table 3 shows the relationship between the percentage of
clones of the S. aureus phylotype and the risk factors of
MRSA pneumonia among all 42 patients. Gastrostomy or
nasogastric tube feeding was significantly negatively corre-
lated with the percentage of clones of S. aureus phylotype
using the molecular method (Table 3).
Discussion
We analyzed the cultivation results and bacterial phylo-
types according to the molecular method using BALF
samples in patients with MRSA cultured from respira-
tory samples, and interestingly, no clones of S. aureus
were detected in the BALF samples in 47.6 % (20/42) of
these patients. Most of the patients (n = 28 of 29; 96.5 %)
treated without anti-MRSA antimicrobials (Group B)
showed favorable clinical outcomes despite the cultivation
of MRSA, and these 28 patients were suspected to have
non-MRSA pneumonia; the cultured MRSA from the re-
spiratory samples might have been due to colonization in
the respiratory tract. In addition, the S. aureus phylotype
was only a minor population (the percentage of clones ≤
10 %) in 67.9 % (19/28) of these 28 patients in Group B ac-
cording to the molecular method, which was compatible
with their clinical courses. Several previous reports have de-
scribed that MRSA is occasionally a non-causative patho-
gen of pneumonia in some patients [23–26] even when
MRSA is cultured from sputum samples, and our results
suggest that even when MRSA was cultured using samples
obtained from the lower respiratory tract, MRSA was clin-
ically considered not to be a causative agent in more than
two-thirds of these patients.
A similar report by Nagaoka et al. showed that approxi-
mately half (51.4 %, 36/70) of the patients were considered
to have true MRSA pneumonia when hospital-acquired
MRSA pneumonia was defined according to the positive re-
sponses and/or clinical demand of anti-MRSA agents with a
positive culture of MRSA and detection of clustered Gram-
positive cocci within polymorphonuclear cells in the
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respiratory samples, such as BALF or transthoracic aspir-
ation [11]. Moreover, at least 66.7 % (28/42) of the patients
were possibly considered to have MRSA colonization, and
MRSA was considered to be a causative pathogen in 33.3 %
(14/42) of the patients in this study. These data suggest that
it remains clinically controversial whether or not MRSA is a
true causative pathogen of pneumonia, even in patients with
MRSA cultured from the lower respiratory samples, and the
ratio of true MRSA pneumonia in these patients might be
lower than previously believed.
Table 1 The clinical characteristics and laboratory findings of 42 patients treated with or without anti-MRSA drugs in this study
Clinical variates Group A Group B P-value
Treated with anti-MRSA drugs Treated without anti-MRSA drugs
(n = 13) (n = 29)
Age ± SD (years) 74.8 ± 10.1 74.6 ± 17.5 0.764
Male: Female 10:3 19:10 0.458
Underlying diseases**
None 2 (15.4 %) 4 (13.8 %) 0.898
Malignancies 1 (7.7 %) 11 (37.9 %) 0.016
Cerebrovascular disorders 5 (38.5 %) 10 (34.5 %) 0.813
Chronic pulmonary diseases 4 (30.8 %) 5 (17.2 %) 0.382
COPD 2 (15.4 %) 2 (6.9 %) 0.469
Bronchiectasis/NTM 1 (7.7 %) 5 (17.2 %) 0.370
Interstitial lung diseases 1 (7.7 %) 1 (3.4 %) 0.621
Diabetes mellitus 4 (30.8 %) 3 (10.3 %) 0.178
Dementia 4 (30.8 %) 6 (20.7 %) 0.519
Heart diseases 4 (30.8 %) 5 (17.2 %) 0.382
Hepatic diseases 1 (7.7 %) 1 (3.4 %) 0.621
Renal diseases 1 (7.7 %) 4 (13.8 %) 0.550
Hematology/Collagen-vascular diseases 1 (7.7 %) 4 (13.8 %) 0.550
ECOG performance status 3-4 75.0 % (9/12) 60.0 % (15/25) 0.371
Use of Glucocorticoid**/Immunosuppresant 1 (7.7 %) 5 (17.2 %) 0.37
Use of gastric tube 1 (7.7 %) 2 (6.9 %) 0.931
Histories/Risks of aspiration 8 (61.5 %) 15 (51.7 %) 0.568
Antibiotic therapy in the preceding 90 days 5 (38.5 %) 7 (24.1 %) 0.387
History of MRSA detection in the preceding 90 days 4 (30.8 %) 5 (17.2 %) 0.382
Type of pneumonia
CAP 0 (0.0 %) 2 (6.9 %) 0.161
HCAP 2 (15.4 %) 15 (51.7 %) 0.015
HAP 11 (84.6 %) 12 (41.3 %) 0.099
Radiologic findings of Chest CT*
Consolidation 7 (63.6 %) 12 (41.4 %) 0.474
Bronchopneumonia 1 (9.1 %) 9 (31.0 %)) 0.052
Complicated with cavitation/abscess formation 0 (0.0 %) 0 (0.0 %) –
Complicated with atelectasis 0 (0.0 %) 3 (10.3 %) 0.083
Centrilobular nodules (DPB-like) 0 (0.0 %) 0 (0.0 %) –
Diffuse alveolar shadow (ARDS-like) 2 (18.2 %) 0 (0.0 %) 0.165
Bronchiectasis 1 (9.1 %) 6 (20.7 %) 0.239
Parapneumonic pleural effusion 5 (45.5 %) 3 (10.3 %) 0.082
SD standard deviation, COPD chronic obstractive pulmonary disease, NTM nontuberculous mycobacterial infection, MRSA methicillin-resistant Staphylococcus aureus, ECOG
Eastern Cooperative Oncology Group, CAP community-acquired pneumonia, HCAP helathcare-associated pneumonia, HAP hospital-acquired pneumonia, CT computed
tomography, DPB diffuse pulmonary bronchiolitis, ARDS acute respiratory distress syndrome
*includes diplicates, **corresponds to prednisolone 5 mg daily or greater
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Table 2 Comparison of Bacteria Between Conventional Cultivation Methods and 16S rDNA Sequencing Analysis in the Bacterial Infection Group
Age Pneumonia type Sputum BALF Prior antibiotics Treatments Clinical outcome
Culture Culture Clone library analysis
Predominant phylotype, % S. aureus
GROUP A
1 72 HAP not analyzed MRSA Staphylococcus aureus 97.5 % 97.5 % ABK VCM ineffective
2 70 VAP not analyzed MRSA Staphylococcus aureus 91.8 % 91.8 % None TEIC effective
3 78 HAP MRSA MRSA Staphylococcus aureus 91.0 % 91.0 % None ABK effective
4 77 HCAP MRSA MRSA Staphylococcus aureus 53.1 % 51.8 % IPM/CS MINO BIPM, PZFX + CLDM,
CZOP + ABK
ineffective
5 65 HAP not analyzed MRSA Staphylococcus aureus 50.0 % 50.0 % MEPM MEPM+VCM effective
6 76 HAP not analyzed MRSA Corynebacterium simulans 41.9 % 8.1 % None VCM ineffective
7 61 HAP S. pneumoniae MRSA MRSA Haemophilus influenzae 35.3 % 3.5 % MEPM MEPM + VCM effective
8 87 HAP MRSA MRSA Corynebacterium spp. 97.8 % 2.2 % SBT/ABPC TEIC effective
9 66 HAP not analyzed H. influenzae, MRSA Haemophilus influenzae 84.0 % 1.1 % None IPM/CS + VCM
SBT/ABPC
effective
10 82 VAP not analyzed MRSA P. aeruginosa Pseudomonas aeruginosa 94.6 % 0.0 % IPM/CS PZFX+VCM ineffective
11 61 HCAP not analyzed MRSA, Aspergillus fumigatus Streptococcus spp. 90.7 % 0.0 % DRPM DPPM PZFX + CLDM/L-
AMB + VCM/TAZ/PIPC
ineffective
12 91 HAP MRSA MRSA Streptococcus oralis 58.5 % 0.0 % MEPM LZD effective
13 87 HAP not analyzed MRSA, Neisseria Neisseria perflava 95.5 % 0.0 % TEIC TEIC, AMK effective
GROUP B
14 81 HAP not analyzed MRSA Staphylococcus aureus 100 % 100.0 % None DRPM effective
15 21 VAP not analyzed MRSA Staphylococcus aureus 88.6 % 88.6 % None MEPM effective
16 73 CAP not analyzed MRSA Staphylococcus aureus 60.8 % 60.8 % None GRX effective
17 76 HCAP MRSA P. aeruginosa MSSA Staphylococcus aureus 57.1 % 57.1 % None TAZ/PIPC ineffective
18 81 HCAP MRSA P. aeruginosa no growth Staphylococcus aureus 55.4 % 55.4 % None CZOP + CLDM effective
19 62 CAP MRSA MRSA Staphylococcus aureus 48.7 % 48.7 % FQ CPFX effective
20 80 HAP MRSA MRSA Streptococcus intermedius 56.5 % 40.6 % None DRPM effective
21 76 HAP MRSA MRSA Corynebacterium spp. 25.3 % 18.4 % TAZ/PIPC SBT/ABPC effective
22 22 HAP not analyzed MRSA, A. baumannii Neisseria elongata 81.2 % 15.1 % TEIC IPM/CS effective
23 81 HCAP MRSA MRSA Streptococcus spp. 46.7 % 12.0 % None LVFX effective
24 85 HAP not analyzed MRSA Streptococcus oralis/mitis 37.3 % 8.0 % CPFX LVFX effective
25 83 HCAP MRSA, E. coli MRSA, E. coli Moraxella catarrhalis 69.2 % 7.7 % None TAZ/PIPC effective
26 76 HAP not analyzed K. pneumoniae, MRSA,
Proteus mirabilis














Table 2 Comparison of Bacteria Between Conventional Cultivation Methods and 16S rDNA Sequencing Analysis in the Bacterial Infection Group (Continued)
27 85 HAP MRSA MRSA Fusobacterium nucleatum 55.7 % 0.0 % None LVFX effective
28 61 HCAP not analyzed MRSA, B. cepacia, F. mortiferum Rothia spp. 45.2 % 0.0 % None MEPM effective
29 45 HAP not analyzed S. maltophilia, MRSA Enterococcus hirae 25.8 % 0.0 % None MEPM effective
30 74 HCAP P. aeruginosa MRSA P. aeruginosa, MRSA Streptococcus salivarius 43.0 % 0.0 % None MEPM effective
31 80 HCAP not analyzed MRSA Streptococcus spp. 98.9 % 0.0 % Unknown LVFX effective
32 80 HCAP not analyzed MRSA Streptococcus spp. 97.4 % 0.0 % Unknown LVFX effective
33 98 HCAP MRSA not analyzed Streptococcus spp. 78.8 % 0.0 % Unknown TAZ/PIPC effective
34 80 HCAP MRSA oral bacteria Neisseria spp. 55.0 % 0.0 % LVFX MEPM effective
35 82 HCAP not analyzed P. aeruginosa, MRSA, Streptococcus Streptococcus oralis/mitis 70.7 % 0.0 % Unknown SBT/ABPC effective
36 64 HCAP not analyzed P. aeruginosa, MRSA Pseudomonas aeruginosa 97.4 % 0.0 % None TAZ/PIPC + LVFX effective
37 86 HCAP MRSA K. pneumoniae, MRSA Lactobacillus spp. 51.1 % 0.0 % None TAZ/PIPC effective
38 80 HCAP E. coli, MRSA oral bacteria Streptococcus spp. 45.2 % 0.0 % None TAZ/PIPC effective
39 93 HCAP not analyzed MRSA, oral bacteria Corynebacterium spp. 94.3 % 0.0 % None LVFX effective
40 81 HAP not analyzed MRSA, E. coli Haemophilus influenzae 34.5 % 0.0 % None TAZ/PIPC effective
41 73 HAP not analyzed Enterobacter cloacae, MRSA Enterobacter asburiae 70.0 % 0.0 % None DRPM effective
42 74 HAP MRSA Corynebacterium, MRSA Corynebacterium simulans 98.9 % 0.0 % TAZ/PIPC TAZ/PIPC effective
Abbreviations: CAP community-acquired pneumonia, healthcare-associated pneumonia, HAP hospital-acquired pneumonia, VAP ventilator-associated pneumonia, MRSA methicillin-resistant Staphylococcus aureus, BALF
bronchoalveolar lavage fluid, ABK arbekacin, VCM vancomycin, TEIC teicoplanin, LZD linezolid, IPM/CS imipenem/cilastatin, MEPM meropenem, DRPM doripenem, BIPM biapenem, CZOP cefozopran, SBT/ABPC sulbactam/














Five of 28 (17.9 %) patients in Group B who showed
good clinical outcomes without anti-MRSA agents dem-
onstrated that the S. aureus phylotype was predominant
among the detected bacterial phylotypes in the samples,
which may be inconsistent with the colonization of
MRSA. The molecular method we used could not evalu-
ate drug resistance, and a differentiation between MRSA
and methicillin-susceptible S. aureus (MSSA) was not
possible in this retrospective study. Spontaneous remis-
sion of MRSA pneumonia is another potential explan-
ation. In addition, there are presently no criteria to
differentiate causative pathogens using the ratio of bac-
terial phylotypes in the samples, thus careful discretion
is necessary to interpret these data, and further studies
are needed to elucidate this issue.
Several guidelines [4, 6–8] and clinical trials [11] have
described the risk factors of MRSA pneumonia. Accord-
ing to a report by Nagaoka et al. [11] that used a mul-
tiple regression analysis for the risk factors of MRSA, a
past history of head and neck, esophageal or stomach
surgery (odds ratio (OR) 8.63), radiological findings of
other than lobar pneumonia (OR 10.2), severity of pneu-
monia with the Pneumonia Patient Outcomes Research
Team (PORT) score 5 (OR 5.23), more than 106 CFU/ml
of MRSA using a quantitative culture (OR 12.8), and a
single cultivation of MRSA (OR 19.9) were significantly
correlated with MRSA pneumonia. More HCAP patients
were observed in Group B than in Group A, however,
no other factors were significantly different between
Groups A and B in this study. When considering the
percentage of clones of the S. aureus phylotype in BALF
samples according to each different risk factor in this
study, only the “use of gastric tube feeding” was inversely
correlated with the percentage of clones of S. aureus
(Table 3), suggesting that such condition may be a clue
to avoid an abuse of anti-MRSA agents.
The analysis using the 16S rRNA gene can detect only
bacterial DNA, and does not equally indicate that the
detected bacterial phylotype causes bacterial infection.
Therefore, we have been investigating and validating this
molecular method in several diseases to compare this
molecular method with the results of cultivation
methods in several settings [12, 13]. Further investiga-
tions for validating this method should be performed.
Study limitation
There are several limitations associated with the present
study. First, the universal primers we used for the mo-
lecular analysis could not amplify all of the bacterial 16S
rRNA genes. The primers we used cover approximately
92 % of the registered bacterial species in the Ribosomal
Database Project II database, however, the remaining un-
detectable bacteria with these primers included no
causative pathogens that have been reported in humans
[19]. Second, approximately 100 clones per each clone li-
brary were analyzed, meaning that bacterial 16S rRNA
gene sequences present at less than 1 % of each sample
may not be detectable using this method. Third, this
study was retrospective, and anti-MRSA agents were ad-
ministered with no particular criteria. Fourth, a quantita-
tive culture and evaluation of neutrophil phagocytosis of
the organisms were not performed. Fifth, study popula-
tion was relatively small and elderly patients were mostly
included in HCAP or HAP patients, and only two CAP
patients were included. Further investigations should be
considered to elucidate the data in younger population.
Conclusion
We evaluated the clinical course and the ratios of bacterial
phylotypes in BALF specimens using the clone library
method and conventional cultivation methods in patients
with MRSA detected by cultivation from respiratory sam-
ples. The results of this study demonstrated that these pa-
tients were heterogeneous, and approximately two-thirds
of these patients might be considered to have MRSA
colonization or non-MRSA pneumonia. In addition, the
results of the cultivation-independent molecular method
we used indicated that the detection of MRSA by cultiva-
tion methods may not correctly reflect the pathogenicity
of MRSA in patients with pneumonia. Further prospective
studies are necessary to elucidate the pathogenicity of
MRSA in pneumonia.
Table 3 Comparison of Bacteria Between Conventional Cultivation Methods and 16S rDNA Sequencing Analysis in the Bacterial
Infection Group
Risk factors (Positive/Negative)** The percentage of clones of MRSA phylotype (%)
Positive Negative P-value
Use of Glucocorticoid**/Immunosuppressant (6/36) 40.2 ± 41.4 19.0 ± 28.3 0.305
Histories/Risks of aspiration (23/19) 18.7 ± 33.2 25.2 ± 29.2 0.422
Antibiotic therapy in the preceding 90 days (12/30) 30.1 ± 40.7 17.5 ± 25.7 0.391
History of pathogens detection in the preceding 90 days* (9/30) 38.2 ± 35.1 15.4 ± 28.9 0.105
*Unknown data in three cases, **“Positive” and “Negative” indicate the number of patients with or without each risk factor, respectively.
Abbreviations: MRSA methicillin-resistant Staphylococcus aureus
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